URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Move over, GLP-1s. A preclinical next-gen obesity drug is stacking five mechanisms (in mice). Also, the NIH funding climate is rougher than ever, Novartis is reshoring more of its manufacturing, and another Alzheimer’s program is scuttled.
The need-to-know this morning
- More pharma earnings: Merck, Bristol Myers Squibb and Eli Lilly
- Notable biotech earnings: Alnylam.
- UniQure said it will submit a marketing application for its Huntington’s disease gene therapy to U.K. regulators in the third quarter.
- Craig Venter, scientist, genomic pioneer and entrepreneur, died.
It’s far harder to get an NIH grant these days
The odds of landing an NIH grant have cratered to near-unsustainable levels. Only 13% of applications were funded last year, STAT’s Anil Oza writes, with even top-scoring proposals no longer having good odds. Now, researchers are scrambling to survive in a system that’s become both hypercompetitive and opaque.
Please follow us:
